The first series A tranche will help commercialise a remedy for metabolic disorders and inflammatory conditions resulting from cardio-metabolic problems.
A-Mansia Biotech, a Belgium-based microbiome research spinout from Université catholique de Louvain (UCL) and Wageningen University and Research, raised €13m ($15.7m) in initial series A funding on Friday.
The amount represents a first close and was provided by investors including Fonds Vives II, the university venture fund of UCL. The spinout has not revealed a target amount for the round.
VC firm Seventure Partners led the round, which also featured state-owned regional development vehicle Société Régionale d’Investissement de Wallonie, Groupe…
